MedTrace Logo

Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI

NCT00780858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 662

Last updated 2015-05-06

No results posted yet for this study

Summary

Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

Conditions

Interventions

DRUG

Ganirelix

Ganirelix 0.25mg s.c every 24 h starting stimulation day 6

Sponsors & Collaborators

  • IVI Madrid

    lead OTHER

Principal Investigators

  • Juan antonio García-Velasco, MD · IVI Madrid

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-12-31
Completion
2011-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00780858 on ClinicalTrials.gov